The effects of a bioavailable curcumin formulation on Alzheimer's disease pathologies: A potential risk for neuroinflammation
Shaun Cade, Clive Prestidge, Xin‐Fu Zhou, Larisa Bobrovskaya · 2024
Read The effects of a bioavailable curcumin formulation on Alzheimer's disease pathologies: A potential risk for neuroinflammation by Shaun Cade, Clive Prestidge, Xin‐Fu Zhou, Larisa Bobrovskaya (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11649387.txt.
Description
Shaun Cade and co-authors tested a turmeric compound in mice bred to model Alzheimer's disease in this 2024 study. The compound, curcumin, had shown promise in earlier mouse work but is poorly absorbed when swallowed. The team used a new form packed into tiny capsules, given in drinking water, to raise how much reaches the body.
The new form did not shrink or reduce the amyloid plaques that mark the disease. It also left the machinery that makes amyloid unchanged. One sign did move the wrong way: a protein tied to irritation in the brain rose overall. The authors warn that pushing the dose of this form may risk inflaming the brain rather than protecting it.
Catalog record
| CREATOR | Shaun Cade, Clive Prestidge, Xin‐Fu Zhou, Larisa Bobrovskaya |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |